RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Quan Capital, a Shanghai healthcare venture firm, closed its second fund with $275 million in commitments, according to media reports. In 2018, Quan announced it would begin fundraising for second fund with a $300 million target, one year after it closed its $150 million initial fund. Quan is very closely allied with Zai Lab. Samantha Du, PhD, heads both companies and other members of Zai’s senior management are also part of Quan’s team. Quan seeks venture and growth investments in disruptive companies globally and in China.
